Advertisement
MRK vs SNY
Which Stock Would AI Choose? Merck & Co. (MRK) vs. Sanofi (SNY) Stock Comparison
Key Takeaways
- MRK has significantly outperformed SNY year-to-date (YTD), with a gain of approximately 12% compared to SNY's 1.5%.
- MRK's market capitalization stands at around $290 billion, dwarfing SNY's $115 billion, reflecting greater scale.
- MRK trades at a lower trailing P/E ratio (price-to-earnings) of 16 versus SNY's 20, suggesting relative value.
- Both stocks benefit from recent regulatory approvals, but MRK shows stronger profit margins at 28% compared to SNY's 17%.
- In recent market activity, SNY has lagged with a 4.6% decline over the past 30 days amid broader underperformance.
Introduction
Merck & Co. (MRK) and Sanofi (SNY) are leading pharmaceutical giants with diversified portfolios in oncology, immunology, and vaccines. This comparison analyzes their recent performance, financial metrics, and market positioning amid evolving healthcare sector dynamics. Investors seeking exposure to stable dividend payers or growth in biologics, as well as traders monitoring short-term momentum, will find insights into relative strengths, such as MRK's robust oncology franchise versus SNY's immunology focus. With both facing upcoming earnings, understanding these contrasts aids informed stock comparison decisions.
MRK Overview and Recent Performance
Merck & Co. (MRK) is a global healthcare leader specializing in innovative medicines, vaccines, and animal health products. Its blockbuster drug Keytruda drives oncology revenue, complemented by Gardasil for HPV prevention. In recent weeks, MRK shares have traded around $117, with YTD gains of 12% and a 52-week range of $73-$125. Sentiment is mixed ahead of Q1 earnings on April 30, influenced by EU approval for RSV preventive Enflonsia, bolstering its pediatric portfolio, though valuation concerns persist amid year-over-year EPS (earnings per share) pressures. TTM revenue reached $65 billion with a 28% profit margin, supported by 5% quarterly revenue growth.
SNY Overview and Recent Performance
Sanofi (SNY), a French multinational, focuses on vaccines, rare diseases, and consumer healthcare, with Dupixent (co-developed with Regeneron) as a key immunology asset. Shares hover near $48, up modestly YTD at 1.5% but within a 52-week range of $43-$56. Recent market activity shows underperformance, with a 4.6% drop over the past 30 days, ahead of Q1 earnings on April 23. Positive developments include EU approvals for Dupixent in pediatric urticaria, yet broader sentiment reflects challenges in growth consistency. TTM revenue was $47 billion, with a 17% profit margin and 7% quarterly revenue growth.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the top performers from over 350 AI trading bots that analyze thousands of tickers across diverse strategies, timeframes, and styles like swing trading, scalping, and sector-specific plays. Only the most suitable for current conditions—boasting annualized returns ranging from 26% to 122%, win rates of 55-88%, and profit factors up to 11.7—earn a spot among the 25 featured. Examples include semiconductor-focused bots with 65-97% returns and gold miners with 52-60% gains, using AI/ML for real-time signals on tickers like NVDA or NEM. These bots offer varied risk profiles, from low-drawdown energy plays to high-momentum semis. Explore Trending AI Robots to identify tools matching your trading approach.
Head-to-Head Comparison
Both MRK and SNY operate diversified pharma business models exposed to patent risks and R&D costs, but MRK emphasizes oncology and vaccines while SNY leans into immunology and rare diseases. Growth drivers differ: MRK's Keytruda pipeline extensions contrast SNY's Dupixent expansions. Recent momentum favors MRK with superior YTD returns and stability, versus SNY's relative lag. Risk factors include regulatory hurdles and competition for both, though MRK's higher ROE (return on equity, 37%) signals better capital efficiency than SNY's 7%. Market sentiment tilts toward MRK pre-earnings, highlighting trade-offs in valuation and sector momentum.
Tickeron AI Verdict
Tickeron’s AI models currently favor MRK over SNY, driven by stronger trend consistency, 12% YTD gains, superior margins, and catalysts like Enflonsia approval. SNY offers value via lower forward P/E but trails in relative performance and momentum. This positioning suggests higher probability of near-term outperformance for MRK in volatile healthcare markets.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MRK is a Hold and SNY is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MRK’s FA Score shows that 3 FA rating(s) are green whileSNY’s FA Score has 1 green FA rating(s).
- MRK’s FA Score: 3 green, 2 red.
- SNY’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MRK’s TA Score shows that 4 TA indicator(s) are bullish while SNY’s TA Score has 2 bullish TA indicator(s).
- MRK’s TA Score: 4 bullish, 6 bearish.
- SNY’s TA Score: 2 bullish, 8 bearish.
Price Growth
MRK (@Pharmaceuticals: Major) experienced а -5.03% price change this week, while SNY (@Pharmaceuticals: Major) price change was -3.92% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.18%. For the same industry, the average monthly price growth was +8.31%, and the average quarterly price growth was +2.32%.
Reported Earning Dates
MRK is expected to report earnings on Aug 04, 2026.
SNY is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.18% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| MRK | SNY | MRK / SNY | |
| Capitalization | 281B | 101B | 278% |
| EBITDA | 19.4B | 8.52B | 228% |
| Gain YTD | 9.765 | -7.701 | -127% |
| P/E Ratio | 32.08 | 18.43 | 174% |
| Revenue | 65.8B | 47.4B | 139% |
| Total Cash | N/A | 5.54B | - |
| Total Debt | 49.1B | 20B | 246% |
MRK | SNY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 10 | 58 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 9 Undervalued | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 51 | 100 | |
SMR RATING 1..100 | 47 | 71 | |
PRICE GROWTH RATING 1..100 | 30 | 60 | |
P/E GROWTH RATING 1..100 | 5 | 41 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SNY's Valuation (3) in the Pharmaceuticals Major industry is in the same range as MRK (9). This means that SNY’s stock grew similarly to MRK’s over the last 12 months.
MRK's Profit vs Risk Rating (51) in the Pharmaceuticals Major industry is somewhat better than the same rating for SNY (100). This means that MRK’s stock grew somewhat faster than SNY’s over the last 12 months.
MRK's SMR Rating (47) in the Pharmaceuticals Major industry is in the same range as SNY (71). This means that MRK’s stock grew similarly to SNY’s over the last 12 months.
MRK's Price Growth Rating (30) in the Pharmaceuticals Major industry is in the same range as SNY (60). This means that MRK’s stock grew similarly to SNY’s over the last 12 months.
MRK's P/E Growth Rating (5) in the Pharmaceuticals Major industry is somewhat better than the same rating for SNY (41). This means that MRK’s stock grew somewhat faster than SNY’s over the last 12 months.
| MRK | SNY | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 50% | 20 days ago 55% |
| Stochastic ODDS (%) | 3 days ago 65% | 3 days ago 54% |
| Momentum ODDS (%) | 3 days ago 55% | 3 days ago 47% |
| MACD ODDS (%) | 3 days ago 62% | 3 days ago 47% |
| TrendWeek ODDS (%) | 3 days ago 49% | 3 days ago 50% |
| TrendMonth ODDS (%) | 3 days ago 53% | 3 days ago 43% |
| Advances ODDS (%) | 4 days ago 54% | 9 days ago 50% |
| Declines ODDS (%) | 6 days ago 51% | 3 days ago 49% |
| BollingerBands ODDS (%) | 3 days ago 54% | 3 days ago 56% |
| Aroon ODDS (%) | 3 days ago 64% | 3 days ago 55% |
Advertisement
SNY and
Correlation & Price change
A.I.dvisor indicates that over the last year, SNY has been loosely correlated with NVS. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if SNY jumps, then NVS could also see price increases.